Physician profile

Abraham D Morganoff

Neuromusculoskeletal Medicine & OMM · Warren, NJ

NPI 1366401945

$1,572.19

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

See the full distribution for Neuromusculoskeletal Medicine & OMM

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $387.73 2019-2021
Genzyme Corporation $307.76 2019-2021
Biogen, INC. $307.47 2019-2021
Sk Life Science, INC. $99.27 2020
Amgen INC. $66.81 2019-2020
Lilly USA, LLC $65.54 2019-2020
Acadia Pharmaceuticals INC $55.37 2019
Supernus Pharmaceuticals, INC. $51.55 2019-2020
Kyowa Kirin, INC. $37.53 2019-2020
Horizon Therapeutics Plc $31.37 2021
Genentech USA, INC. $25.44 2019
Ucb, INC. $22.10 2019
Teva Pharmaceuticals USA, INC. $14.67 2019
Pfizer INC. $14.33 2019
Upsher-Smith Laboratories LLC $13.33 2021
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Neos Therapeutics, LP $13.28 2019
Bausch Health US, LLC $12.35 2019
Mdd US Operations, LLC $12.02 2019
Allergan, INC. $11.67 2020
Eisai INC. $11.45 2019
Amneal Pharmaceuticals LLC $11.15 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Abraham D Morganoff

$1,572.19

in general payments reported 2019-2025

Years
2019-2021
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/743812/abraham-d-morganoff

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.